Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02362035 · ClinicalTrials.gov registry record · Phase 1
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
A Phase 1 study, sponsored by Acerta Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 161
- Enrollment target
NCT02362035 is a Phase 1 study that has completed, run by Acerta Pharma. The registered enrollment target is 161 participants.
The verdict
NCT02362035, a Phase 1 study, has completed, sponsored by Acerta Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 161 participants
- Enrollment target
Study Summary
This study is evaluating the safety, pharmacodynamics (PD), and efficacy of acalabrutinib and pembrolizumab in hematologic malignancies.
Interventions
- DRUG Pembrolizumab
- DRUG Acalabrutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 161 participants |
| Start Date | 2015-02-20 |
| Est. Completion | 2025-10-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02362035
The ClinicalTrials.gov registry entry for NCT02362035 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 161 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Acerta Pharma, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02362035 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02362035 about?
NCT02362035 is a clinical study titled "ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies". This study is evaluating the safety, pharmacodynamics (PD), and efficacy of acalabrutinib and pembrolizumab in hematologic malignancies.
What is the current status of trial NCT02362035?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 161 participants. The study started on 2015-02-20. Estimated completion is 2025-10-27.
What interventions are being tested in trial NCT02362035?
The interventions under investigation include: Pembrolizumab (DRUG), Acalabrutinib (DRUG).
Who is sponsoring clinical trial NCT02362035?
This trial is sponsored by Acerta Pharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.